Filing Flows › 8-K events › DataMeds AI
DataMeds AI: regulation fd disclosure
Form 8-K filed Nov 5, 2026 · items 1.02, 7.01
Regulation FD disclosureDataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
What the filing says
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc . (“DataMeds SI,” “DataMEDS” or the “Company”) (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its Ei
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
DataMeds AI at a glance
DataMeds AI, Q2 2026: revenue $1.8M (-77% year over year), operating margin -412.7%. The chart follows the revenue to costs, profit and cash.
DataMeds AI: every quarter, Q/Q and Y/Y, holders and guidance →
DataMeds AI’s other material 8-Ks
- Oct 26, 2026 — Mergers and acquisitions DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.